Buparlisib plus paclitaxel did not improve overall survival compared to paclitaxel alone in PD-1/PD-L1-pretreated recurrent/metastatic HNSCC patients. The combination showed a higher overall response ...

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

A new report has laid bare how head and neck cancers have "persistently poor" survival rates in our region.

The addition of chemotherapy (CT) to radiation therapy (RT) improves survival rates among a subset of elderly head and neck cancer patients, specifically those ages 71 to 79 with low comorbidity ...

All seven northern Integrated Care Boards have higher rates of head and neck cancer than the England average. Six also have higher death rates, with the North East and North Cumbria the worst in the ...

Enfortumab vedotin and pembrolizumab showed a 39% overall response rate in recurrent/metastatic HNSCC with PD-L1 CPS ≥1. The trial reported a 9.8% complete response rate and a 29.3% partial response ...

Less-invasive robotic surgery for upper airway and digestive track malignant tumors is as effective as other minimally invasive surgical techniques based on patient function and survival, according to ...